This document is a patent publication from the European Patent Office (EPO) detailing a polynucleotide construct intended for the gene therapy of beta-hemoglobinopathies. The publication number is EP2026029716A1, with a publication date of March 18, 2026. It lists relevant International Patent Classification (IPC) codes, including those for genetic engineering, therapeutic preparations, and blood disorders.

As this is a patent publication, it does not impose direct compliance obligations on regulated entities in the same way as a rule or guidance. However, it is relevant for companies operating in the biotechnology and pharmaceutical sectors, particularly those involved in gene therapy research and development, as it pertains to intellectual property in this specific therapeutic area. Compliance officers should note this publication for its implications on patent landscapes and potential future market exclusivity.